Vistin Pharma ASA

VISTN

NO0010734122

Pharmaceuticals

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-05-31 am EDT			5-day change	1st Jan Change
22 ^NOK	-3.51%		-1.79%	-5.58%

May. 23	Vistin Pharma ASA Approves Ordinary Dividend	CI
Apr. 24	Vistin Pharma ASA Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Vistin Pharma ASA Announces Executive Changes

February 16, 2022 at 09:45 am EST

Vistin Pharma ASA announced that CEO Kjell-Erik Nordby is currently on sick-leave, and the Board in Vistin Pharma, with effect from February 16, 2022, has appointed Magnus Tolleshaug as interim CEO. Magnus Tolleshaug has been employed in Vistin Pharma since March 2020 and works as Chief Commercial Officer, with responsibility for the Sales, Marketing & Logistics organization.

Latest news about Vistin Pharma ASA

Vistin Pharma ASA Approves Ordinary Dividend	May. 23	CI
Vistin Pharma ASA Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 24	CI
Transcript : Vistin Pharma ASA, Q1 2024 Earnings Call, Apr 24, 2024	Apr. 24
Vistin Pharma ASA (OB:VISTN) acquired 15% stake in CF Pharma Ltd. for ?1.6 million.	Mar. 03	CI
Vistin Pharma ASA Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 16	CI
Vistin Pharma ASA Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 16	CI
Transcript : Vistin Pharma ASA, Q4 2023 Earnings Call, Feb 16, 2024	Feb. 16
Vistin Pharma ASA Proposes an Ordinary Dividend for the Accounting Year of 2023, Payable on or About 18 June 2024 and 19 November 2024	Feb. 16	CI
Vistin Pharma ASA Announces Cash Dividend, Payable on or About 30 January 2024	Jan. 11	CI
Correction: Vistin Pharma Names Chief Commercial Officer as New CEO	23-10-25	MT
Vistin Pharma Names Chief Commercial Officer as New CEO	23-10-25	MT
Transcript : Vistin Pharma ASA, Q3 2023 Earnings Call, Oct 25, 2023	23-10-25
Vistin Pharma ASA Appoints Magnus Tolleshaug as the New CEO From, 1 January 2024	23-10-25	CI
Vistin Pharma ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-24	CI
Transcript : Vistin Pharma ASA, Q2 2023 Earnings Call, Aug 23, 2023	23-08-23
Vistin Pharma ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-22	CI
Vistin Pharma ASA (OB:VISTN) commences an Equity Buyback Plan, under the authorization approved on May 22, 2023.	23-05-22	CI
Transcript : Vistin Pharma ASA, Q1 2023 Earnings Call, Apr 27, 2023	23-04-27
Vistin Pharma ASA Proposes Dividend	23-04-27	CI
Vistin Pharma ASA Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Vistin Pharma ASA Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-17	CI
Transcript : Vistin Pharma ASA, Q4 2022 Earnings Call, Feb 17, 2023	23-02-17
Vistin Pharma Secures Long-Term Renewable Energy Supply from Norway's Statfraft	22-12-09	MT
Vistin Pharma ASA Enters into Long-Term Renewable Energy Supply Agreement with Statkraft	22-12-09	CI
Transcript : Vistin Pharma ASA, Q3 2022 Earnings Call, Oct 26, 2022	22-10-26

Chart Vistin Pharma ASA

Duration

Period

More charts

Company Profile

Vistin Pharma ASA is a Norway-based holding company, which operates through its subsidiary Vistin Pharma AS. The Company is engaged in the pharmaceuticals industry. The Company is a producer and supplier of Active Pharmaceutical Ingredients (APIs), which are used in medications for diabetes. Vistin Pharma offering such products: Metformin HCl (API); Metformin DC (direct compressible granules); Customized Particle Distribution (PSD) and Premix (Metformin + MgSt, can be delivered on-request). The Companyâs customers are pharmaceutical companies worldwide.

Sector

Pharmaceuticals

Calendar

2024-08-22 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
VISTIN PHARMA ASA	-5.58%	92.79M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+15.91%	41.97B
OTSUKA HOLDINGS CO., LTD.	+22.40%	22.34B
SANDOZ GROUP AG	+18.48%	15.25B
CIPLA LIMITED	+16.12%	14B
ZYDUS LIFESCIENCES LIMITED	+45.12%	12.06B
ONO PHARMACEUTICAL CO., LTD.	-9.58%	6.8B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.18%	5.49B